Hikma Pharmaceuticals Plc Hikma announces injectable licensing agreement

TIDMHIK

Hikma Pharmaceuticals Plc

27 November 2018

London, 27 November 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) today announced a five-year licensing and supply agreement with Hansoh Pharmaceutical Group Co., Ltd. (Hansoh), one of the few research and development-driven Chinese pharmaceutical companies with leading franchises in multiple large and fast-growing therapeutic areas.

The agreement provides Hikma with exclusive rights to market a suite of Hansoh's injectable oncology medicines within the US for the next five years. Hansoh expects to file these products for approval with the FDA within the next 12 months.

"Our partnership with Hansoh will expand Hikma's growing US portfolio of vital injectable oncology medicines and strengthens our ability to serve the growing needs of US hospitals, physicians and patients," said Daniel Motto, Hikma's Executive Vice President of Commercial and Business Development. "We look forward to building relationships with Hansoh and other potential partners whose pharmaceutical products can benefit from our strong commercial relationships and our well-established sales and marketing infrastructure."

"Today one out of every six generic injectable products used in US hospitals is a Hikma product, and we plan to continue adding specialised products like these to our growing portfolio of essential medicines," said Riad Mechlaoui, Hikma's President of Injectables.

-- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

 
 Susan Ringdal                         [phone]/ +44 7776 
  EVP, Strategic Planning and Global    477050 
  Affairs                               [e-mail] 
 Steven Weiss                          [phone]/ [phone] 
  Senior Director, Communications       [e-mail] 
  and Public Affairs 
 

FTI Consulting

 
 Ben Atwell/Brett Pollard    [phone] 
 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

About Hansoh Pharmaceuticals, Inc.

Hansoh Pharma is one of the few research and development-driven Chinese pharmaceutical companies with established leadership positions in some of China's largest and fastest-growing therapeutic areas including central nervous system, oncology, anti-infectives and diabetes. With world-class production facilities and manufacturing quality-management systems that comply with the cGMP requirements of China, the US and Japan, Hansoh Pharma is able to export high-quality injectable pharmaceuticals to developed markets to address significant clinical needs.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRABLBDBBXDBGIL

(END) Dow Jones Newswires

November 27, 2018 04:00 ET (09:00 GMT)